We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 16, 2022

FLT3 and IDH1/2 Inhibitors in AML After Progression on Venetoclax

Leukemia Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia Research
Efficacy of FLT3 and IDH1/2 Inhibitors in Patients with Acute Myeloid Leukemia Previously Treated with Venetoclax
Leuk. Res 2022 Aug 29;[EPub Ahead of Print], JP Bewersdorf, RM Shallis, A Derkach, et al

Further Reading